NEW YORK, Sept 28 - ValiGen has signed a five-year deal to subscribe to all of Celera Genomic’s (NYSE: CRA) database products, the companies said Thursday.
Valigen, of Newton, PA, said it would access the databases through Celera’s web-based Discovery System.
Financial terms of the deal were not disclosed.
" This agreement is the first to provide a biotechnology company of our size with access to all of Celera's databases,” Douglas Watson, president and CEO of ValiGen, said in a statement. “This agreement will allow ValiGen to make optimal use of its integrated functional genomics platform and will thereby enhance and accelerate our capabilities to identify and validate intervention targets.”
Under the terms of the deal ValiGen’s researchers will have access to all databases developed by Celera. These databases consist of the Celera Human Gene Index, Human Genome Database, Drosophila Genome Database, Mouse Genome Database, and the SNP Reference Database.
ValiGen conducts research to profile phenotypes, conduct in vivo validation of targets, and to develop human healthcare, plant, and industrial products.
Shares of Celera were up 1 5/8, or 1.6 percent, at 100 3/4 in morning trading.